



- (51) **International Patent Classification:**
A61K 48/00 (2006.01) *C12N 15/861* (2006.01)
- (21) **International Application Number:**
PCT/US2015/016702
- (22) **International Filing Date:**
19 February 2015 (19.02.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/941,775 19 February 2014 (19.02.2014) US
- (72) **Inventors; and**
- (71) **Applicants :** **BERRY, Jody** [CA/CA]; c/o Cangene Corporation, 155 Innovation Drive, Winnipeg, Manitoba R3T 5Y3 (CA). **MCCLARTY, Grant** [CA/CA]; c/o Cangene Corporation, 155 Innovation Drive, Winnipeg, Manitoba R3T 5Y3 (CA). **WARFIELD, Kelly** [US/US]; c/o Integrated BioTherapeutics, Inc., 21 Firstfield Road, Suite 100, Gaithersburg, Maryland 20878 (US). **JAVAD, Aman Mohammad** [US/US]; c/o Integrated BioTherapeutics, Inc., 21 Firstfield Road, Suite 100, Gaithersburg, Maryland 20878 (US).
- (74) **Agents:** **GETTS, Meghann T.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** EBOLA MONOCLONAL ANTIBODIES




Figure 1

(57) **Abstract:** The present disclosure provides antibodies, and antigen-binding fragments thereof that bind to EBOV glycoprotein. The present disclosure further provides hybridoma cell lines and methods for making and using the compositions provided herein.